Goodwin Releases Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S. 

New publication is a go-to reference on all things biosimilars

Goodwin has released its Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed., a comprehensive reference guide authored by a group of lawyers from Goodwin’s Intellectual Property, Life Sciences, FDA, Products Litigation + Counseling, Antitrust + Competition and Appellate Litigation practices and published by Thomson Reuters.

Goodwin is pleased to offer clients and friends a 10% discount on the purchase of the guide. Use code 10BIOSIM (valid through 12/31/19). To purchase from Thomson Reuters, click here.

Other Publications

Below is a sampling of articles and other publications authored by members of the Big Molecule Watch blog team and other Goodwin attorneys and law clerks on issues relating to biosimilars, pharma or biotech more generally.

*Former Goodwin attorney
**Law clerk